Our Mission
The ACC Nevada Chapter is dedicated to advancing the field of cardiovascular care through innovation, advocacy, and professional development, ensuring that Nevada’s clinicians are equipped to meet the evolving health challenges of our state.
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.
Latest in Cardiology from ACC.org
- ACC Scientific Statement Addresses DOACs in Primary and Secondary Prevention of Thrombotic EventsEven with robust evidence demonstrating their efficacy and safety, direct oral anticoagulants (DOACs) continue to be underused and, at times, inappropriately dosed, particularly in patients at elevated thrombotic risk.
- ACC Scientific Statement Guides Use of Antiplatelet Therapy in Managing ASCVDA new ACC Scientific Statement focused on the management of atherosclerotic cardiovascular disease, aims to help clinicians overcome the perpetual challenge of balancing the risk of ischemia with the risk of bleeding in this patient population.
- Withdrawing vs. Continuing GDMT in Patients With Improved Cardiac Function Post AFib AblationIn patients with atrial fibrillation (AFib) with normal cardiac function and sinus rhythm after catheter ablation, 12% who discontinued guideline-directed medical therapy (GDMT) experienced heart failure (HF) deterioration, while drug-related complications were more likely among patients who continued GDMT...
- Discontinuation of Oral Anticoagulation After AF Catheter Ablation (ALONE-AF): ALONE, but Not the Only OneThe ALONE-AF (Anticoagulation One Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation) trial examined whether discontinuing oral anticoagulation (OAC) in patients with elevated stroke risk after catheter ablation of atrial fibrillation (AFCA) who remain free of atrial arrhythmias in the year after their indexed ablation leads to fewer adverse clinical outcomes.
- ACC CardiaCast: Understanding the Spectrum: Causes and Risks of HTG and sHTGThis episode is part of ACC’s ongoing initiative to recognize the risks and tackle management of Hypertriglyceridemia (HTG) and Severe Hypertriglyceridemia (sHTG).